What is Neoleukin Therapeutics, Inc.'s current stock price?

Neoleukin Therapeutics, Inc. (NLTX) currently trades at USD 3.49. Track real-time price changes and historical performance on AllInvestView.

What sector is Neoleukin Therapeutics, Inc. in?

Neoleukin Therapeutics, Inc. operates in the Health Care sector. AllInvestView lets you analyze sector allocation across your entire portfolio.

Neoleukin Therapeutics, Inc. NLTX · Stock Open Neoleukin Therapeutics, Inc. in new tab

3.49 USD

Add to portfolio

1M 6M YTD 1Y 2Y 5Y Max

Loading chart...

DCF Valuation

Tweak assumptions to recompute fair value for Neoleukin Therapeutics, Inc. (NLTX)

Currency: USD

DCF Assumptions

Revenue growth (YoY) 0.10 Decimal (e.g., 0.10 = 10%). Range allows declines (−50%) to strong growth (+50%).

EBITDA margin 0.30 Decimal (e.g., 0.30 = 30%).

Capex (% Revenue) 0.04 Decimal (e.g., 0.04 = 4%).

Tax rate 0.20 Decimal (e.g., 0.20 = 20%).

Terminal growth (g, %) 3% Percent number (e.g., 3 = 3%).

Cost of Equity (%) 10% Percent number (e.g., 10 = 10%).

Cost of Debt (%) 5% Percent number (e.g., 5 = 5%).

DCF Result

Fair Value (DCF)

—

Current Price

—

Upside

—

WACC

—

Terminal PV

—

Σ PV of FCFs

—

Note: historical bars show reported FCF (for context); forward bars show PV of projected FCF; if no per-year data, totals are shown.

Neoleukin Therapeutics, Inc. Analysis (NLTX)

United States Health Care Official Website Stock

Is Neoleukin Therapeutics, Inc. a good investment? Neoleukin Therapeutics, Inc. (NLTX) is currently trading at 3.49 USD.

Investor FAQ

Does Neoleukin Therapeutics, Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is Neoleukin Therapeutics, Inc.?

Neoleukin Therapeutics, Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

Company Profile

Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma. The company was formerly known as Aquinox Pharmaceuticals, Inc. and changed its name to Neoleukin Therapeutics, Inc. in August 2019. Neoleukin Therapeutics, Inc. was founded in 2003 and is headquartered in Seattle, Washington.

Exchange Ticker

NMS (United States) NLTX

Trades

Dividend History paid per year (USD)

No dividend history available.

Stock Splits

Split Date	Split Ratio to 1
Sept. 25, 2023	1:5
Dec. 19, 2023	1:4

Neoleukin Therapeutics, Inc. NLTX · Stock Open Neoleukin Therapeutics, Inc. in new tab

DCF Valuation

DCF Assumptions

DCF Result

Explore Premium Features

Neoleukin Therapeutics, Inc. Analysis (NLTX)

Investor FAQ

Company Profile

Fundamentals

Under Construction

Neoleukin Therapeutics, Inc. NLTX · Stock Open Neoleukin Therapeutics, Inc. in new tab

DCF Valuation

DCF Assumptions

DCF Result

Explore Premium Features

Neoleukin Therapeutics, Inc. Analysis (NLTX)

Investor FAQ

Company Profile

Explore Premium Features

Fundamentals

Under Construction

Community Discussion

Notifications